Safety creatinine clearance level for platinum chemotherapy in lung cancer patients

Ohara,Gen; Miyazaki,Kunihiko; Kurishima,Koichi; Kagohashi,Katsunori; Ishikawa,Hiroichi; Satoh,Hiroaki; Hizawa,Nobuyuki

doi:10.3892/ol.2011.486

Safety creatinine clearance level for platinum chemotherapy in lung cancer patients

Authors:
- Gen Ohara
- Kunihiko Miyazaki
- Koichi Kurishima
- Katsunori Kagohashi
- Hiroichi Ishikawa
- Hiroaki Satoh
- Nobuyuki Hizawa
View Affiliations

Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Ibaraki 310-0015, Japan, Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan, Division of Respiratory Medicine, Tsukuba Medical Center, Tsubuka, Ibaraki, Japan
Published online on: November 16, 2011 https://doi.org/10.3892/ol.2011.486
Pages: 311-314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was carried out to evaluate whether measured‑creatinine clearance (measured‑CrCl) and Cockcroft and Gault-CrCl (CG‑CrCl) are capable of appropriately detecting a decline in renal function in lung cancer patients, including elderly patients, and to clarify a CrCl level with which to discriminate between patients with or without renal impairment. The measured‑CrCl prior and subsequent to platinum‑based chemotherapy of lung cancer patients was retrospectively analyzed. Measured‑CrCl and CG‑CrCl were evaluated prior and subsequent to platinum‑based chemotherapy for lung cancer. Measured-CrCl and CG‑CrCl in 59 lung cancer patients including 25 patients aged ≥65 years were retrospectively analyzed. In patients treated with carboplatin‑based chemotherapy, measured‑CrCl was indicative of a decline in renal function, whereas CG‑CrCl was not. The optimal measured-CrCl level was <60 ml/min post-pretreatment and >90 ml/min at pre-treatment. In cases with pre‑treatment measured-CrCl levels of >90 ml/min, favorable renal function is necessary in order to carry out platinum-based chemotherapy in lung cancer patients, including the elderly.

View Figures

View References

1	Satoh H, Kurishima K, Nakamura R, et al: Lung cancer in patients aged 80 years and over. Lung Cancer. 65:112–118. 2009.PubMed/NCBI
2	Vamvakas L, Saloustros E, Karampeazis A and Georgoulias V: Advanced non-small-cell lung cancer in the elderly. Clin Lung Cancer. 10:158–167. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lang K, Marciniak MD, Faries D, et al: Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer. 63:264–270. 2009. View Article : Google Scholar : PubMed/NCBI
4	Sanborn RE: Cisplatin versus carboplatin in NSCLC: is there one ‘best’ answer? Curr Treat Options Oncol. 9:326–342. 2008.
5	Thyss A, Saudes L, Otto J, Creisson A, Gaspard MH, Dassonville O, et al: Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol. 12:2121–2125. 1994.PubMed/NCBI
6	Lababede O, Meziane M and Rice T: Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. Chest. 139:183–189. 2011. View Article : Google Scholar : PubMed/NCBI
7	Cockcroft DW and Gault MH: Prediction of creatinine clearance from plasma creatinine. Nephron. 16:31–41. 1976. View Article : Google Scholar
8	Horio M and Orita Y: Comparison of Jaffē rate assay and enzymatic method for the measurement of creatinine clearance. Jap J Nephrol. 38:296–299. 1996.
9	Sweileh WM, Sawalha AF, Zyoud SH, Al-Jabi1 SW and Shraim NY: Prevalence of reduced renal function among diabetic hypertensive patients. Int J Physiol Pathophysiol Pharmacol. 1:41–47. 2009.PubMed/NCBI
10	Wu MC, Lee WJ, Tschen SM, Lin SY, Lee IT, Jeng CY, et al: Predictors of mortality in hospitalized diabetic patients: A 7-year prospective study. Diabetes Res Clin Pract. 80:449–454. 2008.PubMed/NCBI
11	Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, et al: Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 25:206–211. 2004. View Article : Google Scholar : PubMed/NCBI
12	Quoix E: Carboplatin-based Doublet Effective for Elderly Patients with NSCLC. In: Plenary Session at ASCO’s 2010 Annual Meeting (Abstract 2);
13	Kaplan C, Pasternack B, Shah H and Gallo G: Age-related incidence of sclerotic glomeruli in human kidneys. Am J Pathol. 80:227–234. 1975.PubMed/NCBI
14	Tauchi H, Tsuboi K and Sato K: Histology and experimental pathology of senile atrophy of the kidney. Nagoya Med J. 4:71–97. 1958.
15	Levey AS: Measurement of renal function in chronic renal disease. Kidney Int. 38:167–184. 1990. View Article : Google Scholar : PubMed/NCBI
16	Beck LH: Changes in renal function with aging. Clinics in Geriatric Medicine. 11:199–209. 1998.
17	Herig PJ and Carlson RE: Plasma creatinine and renal function in the elderly. JAMA. 248:311982. View Article : Google Scholar : PubMed/NCBI
18	Millward MJ, Webster LK, Toner GC, et al: Carboplatin dosing based on measurement of renal function - experience at the Peter MacCallum Cancer Institute. Aust N Z J Med. 26:372–379. 1996. View Article : Google Scholar
19	Peters AM: Quantification of renal haemodynamics with radionucleotides. Eur J Nucl Med. 18:274–286. 1991. View Article : Google Scholar
20	Fawdry RM, Gruenewald SM, Collins LT and Roberts AJ: Comparative assessment of the techniques for estimation of glomerular filtration rate with 99mTc-DTPA. Eur J Nucl Med. 11:7–12. 1985. View Article : Google Scholar : PubMed/NCBI
21	Rehling M, Møller ML, Thamdrup B, Lund JO and Trap-Jensen J: Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man. Clin Sci (Lond). 66:613–619. 1984.